tirzepatide and bimagrumab Today's TRIUMPH-4 results are a clear signal: the next generation of incretin medications will be more powerful than anything we've seen before. Retatrutide is showing nearly 30% body-weight reduction in clinical trials FDA Approves Tirzepatide, A Potential

The majority of participants 103 of them reported a decrease in migraines overall

On the other hand, the above results establish that the normal body mass index and lower HbA1C levels ( 9) were associated with a lower likelihood of hypoglycemia even after adjusting for the number of T2DM medications (mORadj = 0.288

doi: 10.1016/j.amjmed.2013.07.006 321

360 Wellness adjusts dosing and strategies as your body responds

The delayed gastric emptying effect often attenuates over time with long-acting GLP-1 agonists through tachyphylaxis, though the weight loss and glycemic benefits typically persist

The criteria for Wegovy are BMI over 30 or BMI over 27 PLUS weight-related comorbidities, such as elevated cholesterol and/or triglycerides, high blood pressure, sleep apnea, etc